	US 12,139,762 B2
	Association of genetic variations to diagnose and treat attention-deficit hyperactivity disorder (ADHD)
Hakon Hakonarson, Malvern, PA (US); Berta Almoguera, Philadelphia, PA (US); Lyam Vazquez, Philadelphia, PA (US); and Patrick Sleiman, Philadelphia, PA (US)
Assigned to THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Philadelphia, PA (US)
Filed by THE CHILDREN'S HOSPITAL OF PHILADELPHIA, Philadelphia, PA (US)
Filed on Feb. 16, 2023, as Appl. No. 18/170,241.
Application 18/170,241 is a division of application No. 16/644,313, granted, now 11,591,656, previously published as PCT/US2018/049722, filed on Sep. 6, 2018.
Claims priority of provisional application 62/555,523, filed on Sep. 7, 2017.
Prior Publication US 2023/0313304 A1, Oct. 5, 2023
Int. Cl. C12Q 1/68 (2018.01); C12P 19/34 (2006.01); C12Q 1/6883 (2018.01)

CPC C12Q 1/6883 (2013.01) [C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01)]

6 Claims

1. A method for identifying a therapeutic agent which alters neuronal signaling and/or neuronal cell morphology, comprising

a) providing neuronal cells comprising an A allele of rs2105158;

b) providing neuronal cells which lack said A allele and comprise C alleles of rs2105158;

c) contacting the cells of steps a) and b) with a test agent; and

d) after said contacting, measuring alterations in neuronal signaling and/or morphology of the neuronal cells of step a) relative to neuronal cells of step b); identifying the agent causing said alterations as a modulator of neuronal signaling and/or morphology.